TESARO Inc (TSRO.OQ)
|Market Cap (Mil.):||$1,061.15|
|Shares Outstanding (Mil.):||36.00|
* Futures up: Dow 51 pts, S&P 6.9 pts, Nasdaq 18.5 pts (Updates prices, adds Tesaro news)
- Tesaro Inc said its drug for the prevention of chemotherapy-induced nausea and vomiting met the main goal in a third late-stage trial.
May 12 - Tesaro Inc said its drug for the prevention of chemotherapy-induced nausea and vomiting met the main goal in a third late-stage trial.
(Refiles to fix spelling of "experimental" in paragraph 1)
|Astellas Pharma Inc (4503.T)||¥1,400||-12.00|
|Eisai Co., Ltd (4523.T)||¥4,224||-1.50|
|CHUGAI PHARMACEUTICAL CO., LTD. (4519.T)||¥3,050||+40.00|
|Pfizer Inc. (PFE.N)||$30.42||-0.06|
|Novartis AG (NOVN.VX)||CHF80.40||+0.20|
|Merck & Co., Inc. (MRK.N)||$58.10||-0.01|
|AstraZeneca plc (AZN.L)||4,424.50p||+3.50|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||18,750.00₪||+30.00|
|AbbVie Inc (ABBV.N)||$54.20||-0.28|
|BioMarin Pharmaceutical Inc. (BMRN.OQ)||$61.51||-0.57|
Earnings vs. Estimates
Analyst Research Reports
Provider: ValuEngine, Inc.
TESARO Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
Provider: Zacks Investment Research Inc.
Tesaro Inc (TSRO) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.